Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen

Cancer Research

Volumn 59, Issue 1, 1999, Pages 115-121

  Stan, Alexandru C ^a   Radu, Dorel L ^a   Casares, Sofia ^a   Bona, Constantin A ^a   Brumeanu, Teodor D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CARCINOEMBRYONIC ANTIGEN; DOXORUBICIN;

ANGIOGENESIS; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL LEVEL; COLON CANCER; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; CHICK EMBRYO; DOXORUBICIN; GALACTOSE; HUMANS; IMMUNOCONJUGATES; MICROSCOPY, CONFOCAL; NEOPLASMS, EXPERIMENTAL; TUMOR CELLS, CULTURED;

EID: 0032922077     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Blum, R. H., and Carter, S. K. Adriamycin. A new anticancer drug with significant clinical activity. Ann. Intern. Med., 80: 249-259, 1974.
2. Goldman, R., Facchinetti, T., Bach, D., Raz, A., and Shinitzky, M. A differential interaction of daunomycin, Adriamycin and their derivatives with human erythrocytes and phospholipid bilayers. Biochim. Biophys. Acta, 5/2: 254-269, 1978.
3. Meriwether, W. D., and Bachur, N. R. Inhibition of DNA and RNA metabolism by daunorubicin and Adriamycin in L1210 mouse leukemia. Cancer Res., 32: 1137-1142, 1972.
4. Wang, H., Jiang, Z. G., Wong, Y. W., Dalton, W. S., Futscher, B. W., and Chan, V. T. W. Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIα in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226. Biochem. Biophys. Res. Commun., 237: 217-224, 1997.
5. Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., and Liu, L. F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science (Washington DC), 226: 466-468, 1984.
6. Rahman, Z. U., Frye, D. K., Buzdar, A. U., Smith, T. L., Asmar, L., Champlin, R. E., and Hortobagy, G. N. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with melastatic breast cancer. J. Clin. Oncol., 15: 3171-3177, 1997.
7. Hu, Y. P., Jarillon, S., Dubernet, C., Couvreur, P., and Robert, J. On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Cancer Chemother. Pharmacol., 37: 556-560, 1996.
8. Bennis, S., Chapey, C., Couvreur, P., and Robert, J. Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multi-drug-resistant tumour cells in culture. Eur. J. Cancer, 30A: 89-93, 1994.
9. Sakai, N., Kondo, H., Shikinami, A., Hirata, T., Funakoshi, T., Tanabe, Y., and Yamada, H. Postoperative treatment for malignant intracranial tumors - especially concerning intermittent intra-carotid administration of Adriamycin. No. Shinkei. Geka., 12: 237-243, 1984.
10. Bonstelle, C. T., Kori, S. H., and Rekate, H. Intracarotid chemotherapy of glioblastoma after induced blood-brain barrier disruption. Am. J. Neuroradiol., 4: 810-812, 1983.
11. Black, K. L., King, W. A., and Ikezaki, K. Selective opening of the blood-tumor barrier by intracarotid infusion of leukotriene C4. J. Neurosurg., 72: 912-916, 1990.
12. Nomura, T., Inamura, T., and Black, K. L. Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res., 659: 62-66, 1994.
13. Inamura, T., Nomura, T., Bartus, R. T., and Black, K. L. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drag delivery to brain tumors. J. Neurosurg., 81: 752-758, 1994.
14. Inamura, T., and Black, K. L. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J. Cereb. Blood Flow Metab., 14: 862-870, 1994.
15. Matsukado, K., Inamura, T., Nakano, S., Fukui, M., Bartus, R. T., and Black, K. L. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery, 39: 125-133, 1996.
16. Shimura, T., Teramoto, A., Nakazawa, S., and Aihara, K. A clinicopathological study of malignant glioma done after local administration of chemotherapeutic agents. Clin. Neuropathol., 15: 119-124, 1996.
17. Nakazawa, S., Itoh, Y., Shimura, T., Matsumoto, M., and Yajima, K. New management of brain neoplasms. 2. Local injection of Adriamycin. No. Shinkei. Geka., 11: 821-827, 1983.
18. Shimura, T., Nakazawa, S., Itoh, Y., and Matsumoto, M. Effect of local injections of Adriamycin on survival in malignant brain tumor: histopathological evaluation. Gan. To. Kagaku. Ryoho., 10: 1179-1187, 1983.
19. Shimura, T., and Nakazawa, S. Intraneoplastic local injection of Adriamycin for malignant brain tumor chemotherapy: a clinicopathological study. No. Shinkei. Geka., 8: 35-42, 1980.
20. Jinno, H., Ueda, M., Enomoto, K., Ikeda, T., Kyriakos, P., and Kitajima, M. Effectiveness of an Adriamycin immunoconjugate that recognizes the C-erbB-2 product on breast cancer cell lines. Surg. Today. 26: 501-507, 1996.
21. Zhu, J., Takahashi, H., and Nakazawa, S. Human monoclonal antibody-drug conjugates in the experimental treatment of malignant gliomas: studies in vitro and in vivo. Neurol. Med.-Chir., 34: 279-285, 1994.
22. Hurwitz, E., Arnon, R., Sahar, E., and Danon, Y. A conjugate of Adriamycin and monoclonal antibodies to Thy-1 antigen inhibits human neuroblastoma cells in vitro. Ann. N. Y. Acad. Sci., 417: 125-136, 1983.
23. Shih, L. B., Goldenberg, D. M., Xuan, H., Lu, H., Sharkey, R. M., and Hall, T. C. Anthracycline immunoconjugates prepared by a site-specific linkage via an aminodextran intermediate carrier. Cancer Res., 51: 4192-4198, 1991.
24. Ohyanagi, H., Ishida, H., Ishida, T., Soyama, N., Yamamoto, M., Okumura, S., Kano, Y., Ueda, Y., and Saitoh, Y. A monoclonal antibody, KM10 reactive with human gastrointestinal cancer and its application for immunotherapy. Jpn. J Cancer Res., 79: 1349-1358, 1988.
25. Shouval, D., Adler, R., Wands, J. R., Hurwitz, E., Isselbacher, K. J., and Sela, M. Doxorubicin conjugates of monoclonal antibodies to hepatoma-associated antigens. Proc. Natl. Acad. Sci. USA. 85: 8276-8280, 1988.
26. Takahashi, Y., Ueno, M., Mai, M., and Tsukada, Y. Effect of a conjugate of Adriamycin and an antibody to human α-fetoprotein (AFP) on AFP-producing hepatic tumors. Gan. No. Rinsho., 34: 847-850, 1988.
27. Yu, D. S., Chu, T. M., Yeh, M. Y., Chang, S. Y., Ma, C. P., and Man, S. H. Antitumor activity of doxorubicin-monoclonal antibody conjugate on human bladder cancer. J. Urol., 140: 415-421, 1988.
28. Deguchi, T., Chu, T. M., Leong, S. S., Horozsewicz, J. S., and Lee, C. L. Potential therapeutic effect of Adriamycin-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor. J Urol., 137: 353-358, 1987.
29. Shih, L. B., Goldenberg, D. M., Xuan, H., Lu, H. W., Mattes, M. J., and Hall, T. C. Internalization of an intact doxorubicin immunoconjugate. Cancer Immunol. Immunother., 38: 92-98, 1994.
30. Weber, S., Traunecker, A., Oliveri, F., Gerhard, W., and Karjalainen, K. Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor. Nature (Lond.). 356: 793-796, 1992.
31. Drewinko, B., Romsdahl, M. M., Yang, L. Y., Ahearn, M. J., and Trujillo, J. M. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res., 36: 467-475, 1976.
32. Leibovitz, A., Stinson, J. C., McCombs, W. B., McCoy, C. E., Mazur, K. C., and Mabry, N. D. Classification of human colorectal adenocarcinoma cell lines. Cancer Res., 36: 4562-4569, 1976.
33. Avigad, G. Oxidation rates of some desialylated glycoproteins by galactose oxidase. Arch. Biochem. Biophys., 239: 531-537, 1985.
34. Brumeanu, T. D., Dehazya, P., Wolf, I., and Bona, C. A. Enzymatically mediated, glycosidic conjugation of immunoglobulins with viral epitopes. J. Immunol. Methods, 183: 185-197, 1995.
35. Luk, C. K., and Tannock, I. F. Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines. J. Natl. Cancer Inst. (Bethesda), 81: 55-59, 1989.
36. Corfield, A. P., Higa, H., Paulson, J. C., and Schauer, R. The specificity of viral and bacterial sialidases for α(2-3)-and α(2-6)-linked sialic acids in glycoproteins. Biochim. Biophys. Acta. 744: 121-126, 1983.
37. Becker, K. F., Allmeier, H., and Hollt, V. New mechanisms of hormone secretion: MDR-like gene products as extrusion pumps for hormones? Horm. Metab. Res., 24: 210-213, 1992.